Tenaya Therapeutics

San Francisco, United States Founded: 2016 • Age: 10 yrs
Regenerative and gene therapeutics for heart failure are developed.
Request Access

About Tenaya Therapeutics

Tenaya Therapeutics is a company based in San Francisco (United States) founded in 2016 by Benoit Bruneau and Bruce Conklin.. Tenaya Therapeutics has raised $142 million across 3 funding rounds from investors including State of California, The Column Group and Casdin Capital. The company has 97 employees as of December 31, 2024. Tenaya Therapeutics offers products and services including Gene Therapy Platform, Cellular Regeneration, and Precision Medicine. Tenaya Therapeutics operates in a competitive market with competitors including Senti Biosciences, Portola Pharma, Cellino, Arrakis Therapeutics and Aegerion, among others.

  • Headquarter San Francisco, United States
  • Employees 97 as on 31 Dec, 2024
  • Founders Benoit Bruneau, Bruce Conklin
  • Stage Public
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Tenaya Therapeutics, Inc.
Operational Areas
Healthcare → Healthcare Products & Supplies
Healthcare → Healthcare Products & Supplies
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
    $0
    0
    as on Dec 31, 2024
  • Net Profit
    $-111.13 M
    10.44
    as on Dec 31, 2024
  • EBITDA
    $-107.48 M
    12.27
    as on Dec 31, 2024
  • Total Equity Funding
    $142 M (USD)

    in 3 rounds

  • Latest Funding Round
    $8 M (USD), Grant

    Feb 03, 2025

  • Investors
  • Employee Count
    97

    as on Dec 31, 2024

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

IPO & Listings of Tenaya Therapeutics

Tenaya Therapeutics is a publicly listed company on the NASDAQ with ticker symbol TNYA in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

Exchange: NASDAQ · Ticker: TNYA . Sector: Health technology · USA

Products & Services of Tenaya Therapeutics

Tenaya Therapeutics offers a comprehensive portfolio of products and services, including Gene Therapy Platform, Cellular Regeneration, and Precision Medicine. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Develops gene therapies for treating cardiomyopathies and heart conditions

Focuses on regenerating heart cells to combat disease progression

Tailors therapies based on genetic data for heart disease patients

People of Tenaya Therapeutics
Headcount 50-200
Employee Profiles 47
Board Members and Advisors 19
Employee Profiles
People
Kaela Murphy
Senior Human Resources And Talent Acquisition Specialist
People
Faraz Ali
Chief Executive Officer
People
Whit Tingley
Chief Medical Officer
People
Jay Vora
SVP, Portfolio and Program Management

Unlock access to complete

Board Members and Advisors
people
David Goeddel
Director
people
Catherine Stehman-Breen
Member Board Of Directors
people
Jeffrey T. Walsh
Director
people
R. Sanders Williams
Director

Unlock access to complete

Funding Insights of Tenaya Therapeutics

Tenaya Therapeutics has successfully raised a total of $142M across 3 strategic funding rounds. The most recent funding activity was a Grant round of $8 million completed in February 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 3
  • Last Round Grant — $8.0M
  • First Round

    (06 Dec 2016)

  • Investors Count 4
Date Amount Transaction Name Valuation Lead Investors Investors
Feb, 2025 Amount Grant - Tenaya Therapeutics Valuation

investors

Oct, 2019 Amount Series B - Tenaya Therapeutics Valuation Casdin Capital
Dec, 2016 Amount Series A - Tenaya Therapeutics Valuation

investors

TCG
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Tenaya Therapeutics

Tenaya Therapeutics has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include State of California, The Column Group and Casdin Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Investing in Life Sciences sectors like Healthcare and Biotechnology.
Founded Year Domain Location
Early-stage investments in US life science startups are focused on.
Founded Year Domain Location
Corporate backed venture capital fund investing in multiple sectors
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Tenaya Therapeutics

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Tenaya Therapeutics

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Tenaya Therapeutics Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Tenaya Therapeutics

Tenaya Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Senti Biosciences, Portola Pharma, Cellino, Arrakis Therapeutics and Aegerion, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Cell-based therapies for cancer treatment are developed.
domain founded_year HQ Location
Therapeutics for cardiovascular and autoimmune diseases are developed.
domain founded_year HQ Location
Developer of autologous cell therapies
domain founded_year HQ Location
Provider of tools for the analysis of RNA structures
domain founded_year HQ Location
Innovative pharmaceuticals for cardiovascular and metabolic diseases are developed.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Tenaya Therapeutics

Frequently Asked Questions about Tenaya Therapeutics

When was Tenaya Therapeutics founded?

Tenaya Therapeutics was founded in 2016.

Where is Tenaya Therapeutics located?

Tenaya Therapeutics is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.

Is Tenaya Therapeutics a funded company?

Tenaya Therapeutics is a funded company, having raised a total of $142M across 3 funding rounds to date. The company's 1st funding round was a Series A of $50M, raised on Dec 06, 2016.

How many employees does Tenaya Therapeutics have?

As of Dec 31, 2024, the latest employee count at Tenaya Therapeutics is 97.

What does Tenaya Therapeutics do?

Tenaya Therapeutics was founded in 2016 and is based in San Francisco, United States. Focus is placed on the biotechnology sector, where regenerative and gene therapeutics are developed to address heart failure conditions. The pipeline encompasses MYBPC3 for genetic hypertrophic cardiomyopathy, PKP2 for genetic arrhythmogenic right ventricular cardiomyopathy, DWORF for dilated cardiomyopathy, and HDAV6i for heart failure with preserved ejection fraction. Operations center on advancing these targeted treatments.

Who are the top competitors of Tenaya Therapeutics?

Tenaya Therapeutics's top competitors include Senti Biosciences, Athira Pharma and Orca Bio.

What products or services does Tenaya Therapeutics offer?

Tenaya Therapeutics offers Gene Therapy Platform, Cellular Regeneration, and Precision Medicine.

Is Tenaya Therapeutics publicly traded?

Yes, Tenaya Therapeutics is publicly traded on NASDAQ under the ticker symbol TNYA.

Who are Tenaya Therapeutics's investors?

Tenaya Therapeutics has 4 investors. Key investors include State of California, The Column Group, Casdin Capital, and Google Ventures.

What is Tenaya Therapeutics's ticker symbol?

The ticker symbol of Tenaya Therapeutics is TNYA on NASDAQ.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available